Celsion plunges on Phase III failure for ThermoDox in HCC
This article was originally published in Clinica
Executive Summary
Celsion president and CEO Michael Tardugno offered investors few details during a 31 January conference call about how poorly the company's ThermoDox technology performed in the Phase III HEAT clinical trial in hepatocellular carcinoma (HCC), but the few insights he offered were painful to hear, especially for investors who saw Celsion's stock close down 81.2%.